BioSpace News Archive

Karyopharm Therapeutics Inc. announced preliminary unaudited fourth quarter and full year 2023 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2023 achievements and 2024 objectives.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided its preliminary and unaudited estimates for full-year 2023 revenue and net product sales, corporate updates, and full-year 2024 outlook.

Outset Medical, Inc. today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, and provided 2024 financial guidance.

VIVUS LLC announced pipeline updates and program milestones.

Kriya Therapeutics, Inc., (“Kriya”) a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy.

SenesTech, Inc., the leader in fertility control to manage animal pest populations, announces the expansion of EvolveTM, its innovative soft bait fertility control solution, into the broader market of open field agriculture.

PrognomiQ today announced promising results from the largest, deep multi-omics study conducted to date.

Revance Therapeutics, Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.

Marker Therapeutics, Inc. today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.

Lobe Sciences Ltd. today provided an update from the Company on its progress and achievements in 2023.